The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients.

由新型严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 引起的 2019 冠状病毒病 (COVID-19) 持续大流行，需要制定策略来确定预防性和治疗性候选药物以进入快速临床开发。鉴于先前感染或疫苗引起的免疫记忆的持久性存在不确定性，并且考虑到病毒的攻击率，根除 SARS-CoV-2 可能具有挑战性，这一点尤其正确，这需要疫苗提供异常高的保护。在这里，我们展示了雷洛昔芬（一种具有抗炎和抗病毒特性的选择性雌激素受体调节剂）如何成为一种有吸引力的候选药物，进入临床试验以测试其在早期治疗 COVID-19 患者中的疗效。